Iranian Journal of Pharmaceutical Sciences

Vol. 20 No. 4 (2024)

Analysis of Pharmacotherapy Costs and Outcome of Treatment of Hospitalized Patients with COVID-19 Analysis of Pharmacotherapy costs of COVID-19

Iranian Journal of Pharmaceutical Sciences, Vol. 20 No. 4 (2024), 15 October 2024 , Page 315- 323
https://doi.org/10.22037/ijps.v20i4.45173

Abstract

The COVID-19 pandemic has significantly affected people's lives and healthcare systems worldwide. Therefore, it is important to determine its effects on the economic and health sectors. This study aimed to calculate and analyze the costs and outcomes of COVID-19 treatment, including mortality and recovery, to improve health system planning. This cross-sectional descriptive study analyzed the costs and consequences of COVID-19 treatment in one of the largest referral training centers for patients in Lorestan province, Iran. The study examined hospital documents from the beginning of January to the end of December 2022. The results showed that the recovery rate of patients was approximately 87%, and the average cost per patient was 161 USD. More than 70% of this cost was related to medication and hospital bed expenses. Lopinavir was the most prescribed medication, and Immunoglobulin and Remdesivir had the highest cost share among all medication expenses. Given the significant proportion of medication and hospitalization expenses, it is recommended that the new approach to prescribing medications and managing patient care should be centered around standardized treatment protocols and home-based care. This is particularly crucial in developing countries with limited resources and clinical evidence. It is important to note that the calculation of standard treatment costs has limitations and should be interpreted cautiously.

Keywords:
  • Cost
  • Medicine
  • Pharmacoeconomic
  • Management
  • Outcome
  • Treatment
  • Covid-19
  • Hospitalized patients
  • Lopinavir
  • Immunoglobulin
  • Remdesivir

How to Cite

Hayati, H. (2024). Analysis of Pharmacotherapy Costs and Outcome of Treatment of Hospitalized Patients with COVID-19: Analysis of Pharmacotherapy costs of COVID-19. Iranian Journal of Pharmaceutical Sciences, 20(4), 315–323. https://doi.org/10.22037/ijps.v20i4.45173

References

Yamin, M., Counting the cost of COVID-19. International Journal of Information Technology, 2020. 12(2): p. 311-317.

Vandepitte, S., et al., Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review. Value in Health, 2021. 24(11): p. 1551-1569.

Zheng, S.-q., et al., Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: a China perspective. Research in social and administrative pharmacy, 2021. 17(1): p. 1819-1824.

Bahadur, S., W. Long, and M. Shuaib, Human coronaviruses with emphasis on the COVID-19 outbreak. Virusdisease, 2020. 31(2): p. 80-84.

Nakhaei, K., et al., Direct and indirect cost of COVID-19 patients in Iran. Health policy and technology, 2021. 10(4): p. 100572.

Yavarian, J., et al., First cases of SARS-CoV-2 in Iran, 2020: case series report. Iranian journal of public health, 2020. 49(8): p. 1564.

Tan, W., et al., Is returning to work during the COVID-19 pandemic stressful? A study on immediate mental health status and psychoneuroimmunity prevention measures of Chinese workforce. Brain, behavior, and immunity, 2020. 87: p. 84-92.

Carrera-Hueso, F., Counting the cost of COVID-19 at the peak of the pandemic in Spain. PharmacoEconomics & Outcomes News, 2021. 891: p. 7-13.

Gupta, A.G., C.A. Moyer, and D.T. Stern, The economic impact of quarantine: SARS in Toronto as a case study. Journal of Infection, 2005. 50(5): p. 386-393.

Iqbal, A. and S. Bullard, Estimating the economic cost of the COVID-19 pandemic. Business Economics, 2021. 56(4): p. 212-216.

Jin, H., et al., Economic burden of COVID-19, China, January–March, 2020: a cost-of-illness study. Bulletin of the World Health Organization, 2021. 99(2): p. 112.

Warren, D.K., et al., Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Critical care medicine, 2003. 31(5): p. 1312-1317.

Bartsch, S.M., et al., The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States: A simulation estimate of the direct medical costs and health care resource use associated with COVID-19 infections in the United States. Health affairs, 2020. 39(6): p. 927-935.

Dasta, J.F., et al., Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Critical care medicine, 2005. 33(6): p. 1266-1271.

Cleary, S.M., et al., Cost‐effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa. BMC health services research, 2021. 21(1): p. 1-10.

Hayati, H., et al., Cost-Utility of protocols of BFM-ALL and UK-ALL for treatment of children with acute lymphoblastic leukemia in Iran. Iranian journal of public health, 2018. 47(3): p. 407.

Hayati, H., et al., Cost-Analysis of Treatment of Childhood Acute Lymphoblastic Leukemia Based on UKALL Protocol. Iranian Journal of Pediatrics, 2018. 28(6).

Ghaffari Darab, M., et al., The economic burden of coronavirus disease 2019 (COVID-19): evidence from Iran. BMC Health Services Research, 2021. 21(1): p. 1-7.

Miethke-Morais, A., et al., COVID-19-related hospital cost-outcome analysis: The impact of clinical and demographic factors. Brazilian Journal of Infectious Diseases, 2021. 25.

Bai, G. and H. Zare, Hospital cost structure and the implications on cost management during COVID-19. Journal of general internal medicine, 2020. 35(9): p. 2807-2809.

Carta, A. and C. Conversano, Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients-a hypothetical study. BMC Health Services Research, 2021. 21(1): p. 1-12.

Mirhashemi, S.H., et al., Direct medical cost and cost analysis of COVID-19 in Iran: A multicenter cross-sectional study. International Journal of Critical Illness and Injury Science, 2022. 12(1): p. 10.

Jo, Y., et al. Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa. in Open Forum Infectious Diseases. 2021. Oxford University Press US.

Singh, S., et al., Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. BMJ open, 2021. 11(6): p. e048416.

Cao, B., et al., A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine, 2020.

Rafia, R., et al., A cost-effectiveness analysis of remdesivir for the treatment of hospitalized patients with COVID-19 in England and Wales. Value in Health, 2022. 25(5): p. 761-769.

Li, X.-Z., et al., Treatment of coronavirus disease 2019 in Shandong, China: a cost and affordability analysis. Infectious Diseases of Poverty, 2020. 9(03): p. 31-38.

Congly, S.E., et al., Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. Scientific Reports, 2021. 11(1): p. 1-7.

Singh, T.U., et al., Drug repurposing approach to fight COVID-19. Pharmacological Reports, 2020. 72(6): p. 1479-1508.

30. Xiang, H.-r., et al., Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis. International immunopharmacology, 2021. 96: p. 107732.

Flores-Oria, C.A., et al., Intravenous immunoglobulin as adjuvant therapy for COVID-19: A case report and literature review. SAGE Open Medical Case Reports, 2021. 9: p. 2050313X211029699.

Hayati, H., Comparison of the Unit Cost of Diagnostic Imaging Services Before and During the COVID-19 Pandemic Using the Activity-Based Costing (ABC) Method. Iranian Journal of Radiology, 2022.

  • Abstract Viewed: 316 times
  • IJPS_Volume 20_Issue 4_ Pages 315-323 Downloaded: 342 times

Download Statastics

Developed By

Open Journal Systems

Information